ARTICLE | Analyst Picks & Changes

Analyst picks & changes

January 31, 1994 8:00 AM UTC

Alkermes Inc.

Steve Scala of Cowen & Co. began coverage of Alkermes Inc. with a "strong buy" and a target price of $18 in 12-18 months. Scala said that ALKS's broad drug delivery technology portfolio should reduce risk and allow it to enjoy a sizable portion of the $10 billion drug delivery royalty revenue opportunity in 2000. ...